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Rudolf Schicho1 and Martin Storr2Despite sharing little homology (10–15%) with cannabinoid-1
(CB1) and cannabinoid-2 (CB2) receptors, the G protein-
coupled receptor 55 (GPR55) was initially thought to be a new
member of the cannabinoid receptor family. Apart from being
activated by various exogenous cannabinoids, GPR55 is also
activated by endocannabinoids like anandamide, which is
found in organs with high GPR55 expression such as the brain
and the gastrointestinal (GI) tract. The phylogenetic distance to
the classical CB receptors and its pharmacological
responsiveness to certain cannabinoids suggests that GPR55
may constitute a novel class of cannabinoid receptors. GPR55
influences mechanisms in the nervous system, vasculature,
kidney and bone. Recent research revealed that GPR55 is also
involved in cancer development and inflammatory pain.
Because of its presence in the GI tract, several studies have
started to focus on the involvement of GPR55 in the physiology
and pathophysiology of the gut. The following article intends to
discuss the potential role of GPR55 in GI functions.
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The GPR55 receptor — a G protein-coupled
receptor activated by lysophosphatidylinositol
(LPI) and cannabinoids
Since the discovery that effects of cannabinoids are due to
actual ligand–receptor interaction and not to some kind
of non-specific membrane disturbance, the cannabinoid
(CB) receptors, a family of seven-transmembrane span-
ning (7TM) G protein-coupled receptors (GPCRs), have
become the focus of intense research. Over the years it
has become obvious that the diverse biological effects of
cannabinoids (natural cannabinoids, synthetic cannabi-
noids and endocannabinoids) cannot be explained only
by the actions of the two established CB receptors (CB1
and CB2), but that cannabinoid activity is mediated also
Open access under CC BY-NC-ND license. www.sciencedirect.comby various ionotropic receptors and uncharacterized
GPCRs (reviewed in [1]).
Structure of GPR55
Several years ago, a GeneBank search for transmembrane
regions characteristic of the GPCR family (High
Throughput Genome; HTG) revealed several new
7TM/GPCRs, among them the GPR55 gene [2].
GPR55 was subsequently cloned and soon localized by
Northern blot analysis in human brain and liver as well
as in rat intestine and spleen [2]. The ability of GPR55
to respond to cannabinoids was later documented by
two independent patents [3] indicating that GPR55
may represent a new cannabinoid receptor. Although
GPR55 is activated by certain cannabinoids, the low
sequence homology with CB receptors (10–15%) argues
against a clear affiliation to the historically established
cannabinoid receptor family, despite higher sequence
homologies within the conserved regions [3]. Amino acid
residues at the binding and activity sites of human CB1
and CB2 align poorly with human GPR55 implicating that
GPR55 may not share the same binding pockets with the
classical CB receptors [4]. However, the fact that many
cannabinoid compounds are able to activate GPR55 may
suggest that it belongs to a novel group of cannabinoid
receptors that, like CB1 and CB2, could play a potential
role in the physiology and pathophysiology of the GI tract
[5]. Phylogenetically, GPR55 is part of the purine re-
ceptor cluster of the d group of rhodopsin receptors [6]
together with GPR18, another cannabinoid-responsive
GPCR [7,8]. From other GPCRs closely related to
GPR55 (GPR35, GPR92 and GPR23), no reports have
been published yet as to whether they are activated or
inhibited by cannabinoids [1]. Recent data indicate that
lysophosphatidic acid (LPA) may act as their natural
ligand [9–11]. Rodent GPR55 shows up to 78% homology
with the human GPR55 [12].
Pharmacology and physiology of GPR55
The pharmacology of GPR55 has not yet been resolved
and data are too contradictory as to whether GPR55 can
be unambiguously coined as the ‘third cannabinoid re-
ceptor’ [1]. In GTPgS binding assays of overexpressed
cell systems (mainly HEK293 cells), GPR55 activation
was observed following application of many natural and
synthetic cannabinoids as well as following application of
endocannabinoids like anandamide but these results were
not confirmed in other assays of receptor activation (e.g.
b-arrestin activation [13]). Concerning the endogenous
ligand(s) for GPR55, the only consistent data converge on
a lysophospholipid, namely lysophosphatidylinositol
(LPI). Especially, LPI carrying an arachidonic acidCurrent Opinion in Pharmacology 2012, 12:653–658
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activation [14]. Our knowledge on the physiological role
of GPR55 and whether it could be part of the endocan-
nabinoid system is in its infancy. Because of the lack of
studies with specific antagonists, not much is known yet
about the role of endogenous GPR55 to get a clear picture
of the receptor’s functions. Some data have been reported
from cell types endogenously expressing GPR55 such as
from human neutrophils [15], DRG neurons [16],
PC12 cells [17], endothelial cells [18] and also from
cells genetically lacking GPR55 expression [19,20]. In
addition, GPR55 expression has been found in certain
cancer cells [21,22] and in the endocrine pancreas,
where it has been suggested to play a contributory role
in insulin secretion [19]. In human neutrophils, GPR55
augments migratory responses of CB2 to 2-arachidonoyl
glycerol (2-AG) at the level of small GTPases, such as
Rac2 and Cdc42 [15] whereas in endothelial cells,
activation of GPR55 causes Ca++ mobilization, which
is, depending on the status of integrin clustering, inhib-
ited by CB1 activity [18
]. Both findings direct to the
intriguing possibility that an interaction may exist be-
tween GPR55 and CB receptors in physiological and
pathophysiological mechanisms triggered by endocanna-
binoids. In this context, it is noteworthy that the CB1
antagonists SR141716A and AM251 also act as GPR55
agonists [23]. The main differences between GPR55 and
CB receptors not only lie in their low homology but also in
the activation of different downstream G proteins and
downstream signals. In neurons, for instance, CB1 signals
through Gi/o proteins, inhibits voltage gated Ca
++ chan-
nels and activates A-type and inwardly rectifying K+
currents [24]. In contrast to CB receptors, GPR55 signals
through Ga12 and Gq proteins, activates downstream small
G proteins like RhoA and increases Ca++ release and K+
typeM-currents [16]. In osteoclasts, LPI was also shown
to stimulate Rho, an effect that was absent in GPR55/
mice [20]. It seems that GPR55 initiates mostly excitatory
and not inhibitory effects, which is in contrast to the role of
the classical CB receptors, which mostly initiate inhibitory
effects. In line with this concept, GPR55 has been impli-
cated in the development of neuropathic and inflammatory
pain [25]. The reader is referred to several recently
published excellent reviews on GPR55 pharmacology
and physiology [26,27,28,29,30].
Is there a functional role for GPR55 in the GI
tract?
CB1 receptors are known to be involved in several motor
functions of the GI tract like esophageal sphincter relax-
ation and gastric emptying (reviewed in [31]) while CB2
receptors show no involvement in motility, at least not in
physiological conditions. However, data have accumu-
lated showing that CB2 may come into power in situations
during intestinal inflammation [32,33,34,35]. Since
GPR55 can be activated by endogenous and exogenous
cannabinoids we discuss in the following paragraphs theCurrent Opinion in Pharmacology 2012, 12:653–658possibility that GPR55 may have a functional role in GI
physiology and pathophysiology.
Motility and inflammation
Similar to CB1 and CB2 (reviewed in [36]), expression of
GPR55 can be found throughout the GI tract, although a
detailed description of tissues and cells expressing
GPR55 is still lacking. Real time and semiquantitative
PCR show that GPR55 is present in duodenum, jejunum,
ileum and the colon of rodents [12,37,38]. In particular,
GPR55 expression is found in mucosal scrapings and in
longitudinal-myenteric plexus preparations of the colon
indicating that the receptor is most likely present in both,
gastrointestinal epithelial cells and in gastrointestinal
enteric neurons [38]. Additionally, Lin et al. were able
to detect GPR55 in enteric neurons of the rat ileum by
immunohistochemistry [37]. The study showed that the
expression of GPR55 was higher in rats treated with
lipopolysaccharide (LPS) than in control animals, indi-
cating that GPR55 may be involved in the response of the
gut to intestinal inflammation [37]. The authors also
suggested that immunohistochemical expression of
GPR55 was increased in enteric neurons following LPS
treatment, though they did not provide any quantitative
data to corroborate this finding. Nevertheless, the detec-
tion of GPR55 in enteric neurons raises the possibility
that GPR55 has a role in gastrointestinal functions, such
as motility and secretion. In support of this hypothesis,
the atypical cannabinoid O-1602 (a GPR55 agonist that
has shown GTPgS activation in membranes of human
recombinant GPR55-expressing cells with an EC50 of 1.4
[39] and 13 nM [12]), reduced spontaneous contraction
in the rat ileum at 0.1 mM while in the colon, only con-
tractions that were induced by LPS were decreased in a
dose dependent manner [37]. In contrast, O-1602 had no
effect on the membrane potential in the jejunum of
untreated mice [37]. This indicates that, depending on
the part of the GI tract, GPR55 is probably involved in
pathophysiological as well as physiological motor func-
tions. Whether relaxation of gut segments by O-1602 is an
entirely GPR55 dependent process is uncertain because
of its off-target effects. Thus, O-1602 has been shown to
retain vasodilatory [39], orexigenic [40] and anti-inflam-
matory activities [38] in GPR55/ mice. However, a
very recent study demonstrated that O-1602 concen-
tration-dependently reduced electrical field-induced con-
tractions in the colon strips from wild-type and CB1
//
CB2
/ knockout mice, an effect that was significantly
inhibited in GPR55/ knockout mice [41]. Interestingly,
under physiological conditions, the inverse CB1 agonist
AM251, identified as a GPR55 agonist [23], increased
upper GI transit and whole gut transit in mice, but had no
effect on colonic expulsion [42].
On the basis of the assumption that cannabidiol (CBD)
acts as a GPR55 antagonist (CBD was shown to antagon-
ize GPR55 activity to the CB receptor agonist CP55940www.sciencedirect.com
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]) the effect of CBD on gut
motility was investigated after LPS treatment [37]. LPS
increasedGPR55mRNA expression in rat duodenum and
ileum and inhibited intestinal motility in mice while
CBD counteracted the slowed GI motility, as measured
by the upper GI transit time. CBD also normalized the
LPS-induced inhibition of isolated rat smooth muscle
strips. However, CBD had no effect on GI transit in
normal mice or on the resting membrane potential of
jejunum smooth muscle suggesting that an involvement
of GPR55 in GI motility is more prevalent during inflam-
matory than healthy conditions. Upregulation of GPR55
during inflammation may demask the antagonistic effect
of CBD on GPR55, though this remains speculative. In
this respect, the behavior of GPR55 resembles that of the
CB2 receptor which is also increased in inflammatory
conditions, such as IBD [32] and which modulates motor
functions only in an inflammatory state [33]. The exact
mechanism of GPR55 in regulating GI motility remains
elusive until a specific GPR55 antagonist is available. In
the meantime, experiments in GPR55/mice may be an
option to address these questions.
The potential role of GPR55 in intestinal inflammation
has been also addressed in experimental colitis [38].
There, the effects of O-1602 were investigated in
CB1
//CB2
/ and GPR55/ mice that had been sub-
mitted to dextran sulfate sodium (DSS) which induces
inflammation of the colon. O-1602 was still effective inFigure 1
GPR55 knock
DSS + vehicle
Hematoxylin/eosin staining of colon wall sections from GPR55 knockout mic
1602 (or vehicle) twice daily. The putative GPR55 agonist O-1602 is still effe
mucosa is destructed in the colon of DSS + vehicle-treated mice and there
damage, cell infiltration and colon thickness decreased noticeably in the O-
www.sciencedirect.compreventing colitis in these knockout mice suggesting that
the compound had caused an improvement via unidenti-
fied targets (Figure 1). The authors also noted that the
severity of the colitis was slightly but significantly lower
in the GPR55/ mice than in the respective wild types.
The finding favors the hypothesis that GPR55 may play a
pro-inflammatory role in GI inflammation.
Secretion and mucosal homeostasis
A possible involvement of GPR55 in intestinal secretion
remains speculative as this has not been addressed yet.
GPR55 is found at sites of the GI tract known to be
involved in secretory processes, that is, in the mucosa
(mucosal scrapings) of the colon [38] and in the enteric
nervous system [37]which is known to control secretion via
intrinsic neurons. A role for GPR55 in secretory processes
and mucosal homeostasis is therefore conceivable.
Central regulation of gut motility, food intake and emesis
Since GPR55 is expressed in the brain [2] it could partici-
pate in centralmechanisms that influence certain functions
of the gut. Thus, GPR55 transcripts were demonstrated in
the brainstem, which houses the dorsal motor nucleus of
the vagal nerve, as well as in the hypothalamus where
centers related to energy household are located [2,12].
This suggests that GPR55 may play a role in food intake.
Anandamide and other acylethanolamides such as palmi-
toylethanolamide (PEA) and oleoylethanolamide (OEA)
activate CBs and GPR55 and induce or inhibit food intakeouts
DSS + O-1602
Current Opinion in Pharmacology
e exposed to dextran sulfate sodium (DSS) and treated with 5 mg/kg O-
ctive in decreasing the severity of colitis in GPR55 knockout mice. The
is an increased infiltration of immunocytes in the submucosa. Mucosal
1602-treated group. Calibration bar: 100 mm.
Current Opinion in Pharmacology 2012, 12:653–658
656 Gastrointestinal[43,44]. OEA is widely produced in the intestine and
functions as a potent inhibitor of food intake [45], however,
unlike PEA, it is a weakGPR55 agonist [12]. As with CB1,
GPR55 expression could be effected by different levels of
anandamide. In the brain, for instance, levels of ananda-
mide were shown to be regulated by fasting [46] and diet
composition [47]. The same applies for the gut where
anandamide was found to be increased in the small
intestine, but not in the stomach, 24 hours after fasting
[48]. A recent article describes that a missense polymorph-
ism in the GPR55 gene was associated with Anorexia
nervosa [49] supporting the idea that GPR55 may play a
role in the regulation of food intake.
Emetic reflexes are controlled by CB receptors in the
brainstem [50,51]. Vagal afferents express CB1 receptors
which are subject to plastic changes depending on the
state of fasting [52]. It would be interesting to determine
whether GPR55 is expressed in the nodose ganglion and
whether it colocalizes or interacts with CB1 receptors
thereby influencing emesis. Against the idea that
GPR55 plays a role in eating disorders it might be argued
that GPR55/mice do not differ from wild types in their
body weights and the amount of their food intake
[25,40]. Likewise, the GPR55 agonist O-1602 induced
food intake in mice when given icv [40] and this effect
persisted in GPR55/ mice questioning a major role of
GPR55 in food intake.
Is GPR55 involved in GI mechanoreception?
GPR55 was detected in large diameter dorsal root ganglia
cells known to represent mechanoreceptors [16]. This
implicates that extrinsic sensory nerve fibers expressing
GPR55 very likely innervate the GI tract. GPR55 may be
therefore involved in mechanosensation of the GI tract
and eventually in the control of GI pain. Splanchnic
mechanoreceptors arising from dorsal root ganglia innerv-
ate the GI tract at a high percentage [53,54] and have
polymodal functions, that is, they can also act as nocicep-
tors [54] or obtain this ability under brief inflammation
[55]. A role for GPR55 in mechanoreception and pain is
supported by a study of Staton et al. who revealed a pro-
inflammatory role of GPR55 in mechanical hyperalgesia
by demonstrating that GPR55/ mice failed to develop
mechanical hyperalgesia for 2 weeks after intraplantar
administration of Freund’s complete adjuvants or for 28
days following partial ligation of the sciatic nerve [25].
On the basis of these observations, GPR55 could play a
pro-nociceptive role in the GI tract and contribute to
hyperalgesic mechanisms in visceral neurons that
underlie the development of irritable bowel syndrome
[56]. However, O-1602 did not alter responses to noxious
colorectal distension in rats [57] which somewhat argues
against an involvement of GPR55 in visceral nociception,
but as already mentioned above, the in vivo pharmacology
of O-1602 may not depend on GPR55. Functional studies
addressing the involvement of GPR55 in intestinalCurrent Opinion in Pharmacology 2012, 12:653–658mechanoreception have not yet been performed as
specific GPR55 antagonists are not yet available. The
recent identification of a GPR55 agonist binding site is a
promising move to be able to investigate specific GPR55
effects in the near future [58].
Concluding remarks
Despite the paucity of studies on the role of GPR55 in the
GI tract, we can positively assume that GPR55 is involved
in the regulation of GI functions under physiological and
pathophysiological conditions. The expression of GPR55
in brain areas known to govern energy household and
bowel functions as well as in enteric epithelial cells and
enteric neurons suggests that GPR55 is likely involved in
GI processes such as motility and possibly secretion. Its
upregulation in gut tissue after systemic inflammation
indicates that GPR55 may play a role in pathophysiolo-
gical mechanisms of intestinal inflammation and this
seems to hold true for experimental inflammatory con-
ditions of different kinds. Additionally, the presence of
GPR55 in mechanoreceptors raises the intriguing possib-
ility that GPR55 may have a role in the regulation of gut
motility via extrinsic nerve fibers, provided that GPR55 is
located on mechanoreceptors innervating the GI tract. It
will be interesting to find out whether GPR55 interacts
with classical CB receptors in response to endocannabi-
noids in the GI tract and in brain areas affecting GI
functions and whether GPR55 may have a role in dis-
orders of food intake. Future studies involving selective
agonists, antagonists and possibly GPR55/ mice are
warranted to follow the promising evidence that
GPR55 is crucially involved in the regulation of GI
function in health and disease and to facilitate possible
translation into future treatments of GI diseases.
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